Business Context and Reporting Period
Seastar Medical Holding Corp (ICU) filed this Form 8-K on March 15, 2023, to disclose the entry into a Material Definitive Agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to sell senior unsecured convertible notes and warrants to an institutional investor.
- Total Potential Principal: Up to approximately $9.8 million across up to four closings.
- Initial Closing Proceeds: Net proceeds of $2,370,000 received on March 15, 2023, after an 8% original issue discount and legal fees.
- Initial Note Principal: $3,260,869.57.
- Interest Rate: 7% per annum.
- Maturity Date: June 15, 2024 (15 months from issuance).
- Conversion Price: Initial conversion price of $2.70 per share.
- Warrant Exercise Price: $2.97 per share, exercisable for 5 years.
Material Changes and Debt Structure
The filing details a significant change in the Company's capital structure through the issuance of convertible debt.
- Convertible Notes: The Notes are redeemable at the Company's discretion and contain standard covenants. Events of default include failure to pay, bankruptcy, or failure to file SEC reports.
- Future Closings: A second closing is scheduled for an additional $2,173,913.04 in principal. Third and fourth closings (each for $2,173,913.04) are at the Company's option, contingent on stockholder approval for issuances exceeding 19.99% of outstanding shares and the effectiveness of a registration statement.
- Existing Debt Amendments: The Company amended promissory notes with Maxim Group LLC, LM Funding America, Inc., and LMFAO Sponsor, LLC, extending their maturity dates to June 15, 2024, aligning them with the new Notes.
Outlook, Risks, and Contingencies
Management has outlined specific conditions and risks associated with the financing:
- Registration Rights: The Company must file a resale registration statement with the SEC. Failure to meet obligations may result in liquidated damages.
- Expiration of Rights: The right to effect the third and fourth closings terminates automatically if not executed within one year of the Initial Closing Date.
- Dilution Risk: Conversion of Notes and exercise of Warrants will increase the number of outstanding shares. Future closings require stockholder approval to comply with Nasdaq rules regarding share issuance limits.
- Liquidity: The transaction provides immediate liquidity of $2.37 million, with potential for additional capital if conditions for subsequent closings are met.
Investor Verification Checklist
- Verify the effectiveness of the registration statement required for the resale of shares underlying the Notes and Warrants.
- Confirm whether stockholder approval has been obtained or is scheduled for the issuance of shares exceeding 19.99% of outstanding shares (required for 3rd and 4th closings).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific redemption triggers and default provisions.
- Monitor the Company's ability to meet the conditions for the second, third, and fourth closings to realize the full $9.8 million potential principal.